VRXAW NASDAQ
Veraxa Biotech AG
1W: -48.1%
1M: -63.7%
3M: -77.8%
YTD: -80.9%
$0.04
-0.01 (-12.53%)
Weekly Expected Move ±41.2%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.9M
52W Range0.0351-0.35
Volume994,412
Avg Volume57,753
Beta0.60
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChristoph Antz
Employees47
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-10
Websiteveraxa.com
Im Neuenheimer Feld 584
Heidelberg, ZH 69120
DE
Heidelberg, ZH 69120
DE
About Veraxa Biotech AG
Veraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
Latest News
No recent news
Recent Insider Trades
No insider trades found